| --- | --- | --- | |---------------------------------|-------|----------------------| | | | | | | | | | | | | | August 8, 2024 Q2 2024 Results | | | | | | We engineer enzymes | Forward Looking Statements 1 These slides contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results or levels of activity, ...

Codexis (CDXS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -23.08%. A quarter ago, it was expected that this producer of custom industrial enzymes would post a loss of $0.17 per share when it actually produced a loss of $0.16, delivering a surprise of 5.88%. Over the last four quarters, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34705 ___________________________ Codexis, Inc. (Exact name of registrant as specified in its charter) _________________________ ...

Exhibit 99.1 Codexis Reports Second Quarter 2024 Financial Results Company Reiterates Full-year Financial Guidance; On Track to Achieve Product Revenue Growth of at Least 10% vs. FY2023 Excluding Enzyme Sales Related to PAXLOVID™ Anticipate Entering First Technical Collaboration for ECO Synthesis™ Manufacturing Platform by End of Year REDWOOD CITY, Calif., August 8, 2024 -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the second quarter ended June ...

REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website ...

About Codexis REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Codexis is a leading enzyme engineering company leveraging its propr ...

REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Global Healthcare Conference, being held June 5-6, 2024, in New York, New York. Management will participate in a fireside chat on Wednesday, June 5, 2024, at 11:30 am ET. A live webcast of the event will be available here and in the Investor Relations section of the Company's website, http://ir.codexis.com. A replay will be archived ...

For More Information The panel will take place on Wednesday, May 22, 2024, at 4:25 pm ET. A live webcast of the event will be available here and in the Investor Relations section of the Company's website, https://www.codexis.com/investors. A replay will be archived for 90 days following the event. About Codexis Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of prote ...

REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled, "Sustainable API Manufacturing" at the TD Cowen 2nd Annual Sustainability Week, being held virtually May 21-23, 2024. During the presentation, Management will highlight the potential benefits of an enzymatic route of synthesis in the manufacture of small molecule and siRNA therapeutics. Codexis is a leading enzym ...

Codexis, Inc. (NASDAQ:CDXS) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Carrie McKim - Director, Investor Relations Stephen Dilly - President & Chief Executive Officer Stefan Lutz - Senior Vice President, Research Kevin Norrett - Chief Operating Officer Sri Ryali - Chief Financial Officer Conference Call Participants Matt Stanton - Jefferies Evan Stampler - Stifel Matt Hewitt - Craig-Hallum Operator Welcome to the Codexis' First Quarter 2024 Earnings Call. [Operator Instruct ...